SARS-CoV2 Infection in a Multiple Sclerosis Patient Treated with Natalizumab – A Case Presentation

1. Lai CC, Ko WC, Lee PI, Jean SS, Hsueh PR. Extra-respiratory manifestations of COVID-19 [published online ahead of print, 2020 May 22]. Int J Antimicrob Agents. 2020;106024. doi:10.1016/j. ijantimicag.2020.106024Search in Google Scholar

2. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China [published correction appears in Lancet. 2020 Jan 30;:]. Lancet. 2020;395(10223):497-506. doi:10.1016/S0140-6736(20)30183-510.1016/S0140-6736(20)30183-5Search in Google Scholar

3. Willis MD, Robertson NP. Multiple sclerosis and the risk of infection: considerations in the threat of the novel coronavirus, COVID-19/SARSCoV-2. J Neurol. 2020;267(5):1567-1569. doi:10.1007/s00415-020-09822-310.1007/s00415-020-09822-3716316932303837Search in Google Scholar

4. Baker D, Amor S, Kang AS, Schmierer K, Giovannoni G. The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic. Mult Scler Relat Disord. 2020;43:102174. doi:10.1016/j.msard.2020.10217410.1016/j.msard.2020.102174721432332464584Search in Google Scholar

5. Gandhi S, Jakimovski D, Ahmed R, et al. Use of natalizumab in multiple sclerosis: current perspectives. Expert Opin Biol Ther. 2016;16(9):1151-1162. doi:10.1080/14712598.2016.121381010.1080/14712598.2016.121381027413840Search in Google Scholar

6. Sigrist CJ, Bridge A, Le Mercier P. A potential role for integrins in host cell entry by SARS-CoV-2. Antiviral Res. 2020;177:104759. doi:10.1016/j. antiviral.2020.104759Search in Google Scholar

7. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270-273. doi:10.1038/s41586-020-2012-710.1038/s41586-020-2012-7709541832015507Search in Google Scholar

8. Tresoldi I, Sangiuolo CF, Manzari V, Modesti A. SARS-COV-2 and infectivity: Possible increase in infectivity associated to integrin motif expression [published online ahead of print, 2020 Apr 4]. J Med Virol. 2020;10.1002/jmv.25831. doi:10.1002/jmv.2583110.1002/jmv.25831722826632246503Search in Google Scholar

9. Aguirre C, Meca-Lallana V, Barrios-Blandino A, Del Río B, Vivancos J. Covid-19 in a patient with multiple sclerosis treated with natalizumab: May the blockade of integrins have a protective role? [published online ahead of print, 2020 Jun 3]. Mult Scler Relat Disord. 2020;44:102250. doi:10.1016/j.msard.2020.10225010.1016/j.msard.2020.102250783167132531754Search in Google Scholar

10. ApÓstolos-Pereira SL, Silva GD, Disserol CCD, et al. Management of central nervous system demyelinating diseases during the coronavirus disease 2019 pandemic: a practical approach. Arq Neuropsiquiatr. 2020;78(7):430-439. doi:10.1590/0004-282X2020005610.1590/0004-282x2020005632609290Search in Google Scholar

11. Zheng C, Kar I, Chen CK, et al. Multiple Sclerosis Disease-Modifying Therapy and the COVID-19 Pandemic: Implications on the Risk of Infection and Future Vaccination [published online ahead of print, 2020 Aug 11]. CNS Drugs. 2020;1-18. doi:10.1007/s40263-020-00756-y10.1007/s40263-020-00756-y741785032780300Search in Google Scholar

12. Safavi F, Nourbakhsh B, Azimi AR. B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran. Mult Scler Relat Disord. 2020;43:102195. doi:10.1016/j.msard.2020.10219510.1016/j.msard.2020.102195721938932460086Search in Google Scholar

13. Zhovtis Ryerson L, Frohman TC, Foley J, et al. Extended interval dosing of natalizumab in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2016;87(8):885-889. doi:10.1136/jnnp-2015-31294010.1136/jnnp-2015-31294026917698Search in Google Scholar

14. Borriello G, Ianniello A. COVID-19 occurring during Natalizumab treatment: a case report in a patient with extended interval dosing approach. Mult Scler Relat Disord. 2020;41:102165. doi:10.1016/j. msard.2020.102165Search in Google Scholar